|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 89 No. 11 (June 1), 1997:
pp. 3945-3950
RAPID COMMUNICATION
The t(11;16)(q23;p13) Translocation in Myelodysplastic Syndrome Fuses the MLL Gene to the CBP Gene
By
Tomohiko Taki,
Masahiro Sako,
Masahiro Tsuchida, and
Yasuhide Hayashi
From the Department of Pediatrics, Faculty of Medicine, University of Tokyo, Tokyo; the Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu; the Department of Pediatrics, Osaka City General Hospital, Osaka; and the Department of Internal Medicine, Ibaraki Children's Hospital, Mito, Japan.
 |
ABSTRACT |
The recurrent translocation t(11; 16)(q23; p13) has been reported to be associated with therapy-related acute leukemia. The MLL gene involved in other 11q23 abnormalities was also rearranged by this translocation. We analyzed two patients with myelodysplastic syndrome with t(11; 16) and showed that the MLL gene on 11q23 was fused with CREB-binding protein (CBP) gene on 16p13 in these patients. The CBP gene encodes a transcriptional adaptor/coactivator protein and it is mutated in patients with Rubinstein-Taybi syndrome. The CBP gene is also involved in acute myeloid leukemia (AML) with t(8; 16)(p11; p13). In-frame MLL-CBP fusion transcripts combine the MLL AT-hook motifs and DNA methyltransferase homology region with a largely intact CBP. Our results combined with the finding of the MOZ-CBP fusion in t(8; 16)-AML suggest that the CBP gene may be associated with leukemogenesis through translocations.
| |
INTRODUCTION |
CHROMOSOMAL translocations are the most common genetic events observed in hematopoietic malignancies.1,2 It has been thought that specific genes are associated with specific translocations.3 However, recent molecular and cytogenetic studies have shown that some genes involved in specific translocations are also associated with other translocations, such as the AML1 gene in t(8; 21)-acute myeloid leukemia (AML)4 and t(12; 21)-acute lymphoblastic leukemia (ALL),5 and the NPM gene in t(2; 5)-non-Hodgkin's lymphoma (NHL)6 and the t(3; 5)-myelodysplastic syndrome (MDS),7 and that some tumor-suppressor genes are occasionally associated with chromosomal translocations.8,9 The MLL gene10 (also called ALL-1, HRX, and Htrx-1) has been identified in 11q23 translocations,11-13 and its rearrangement was found in the majority of infant14-16 and secondary leukemias.17,18 This gene forms fusion transcripts with over 10 partner genes.11,12,19,20 However, it remains to be elucidated whether the MLL gene, the partner genes, or the fusion transcripts play a critical role in leukemogenesis. The CREB-binding protein (CBP) gene, encoding a transcriptional adaptor/coactivator protein, resides on 16p1321 and it is mutated in patients with Rubinstein-Taybi syndrome.22 Recently, the CBP gene was found to be translocated in AML with t(8; 16)(p11; p13).23,24 The recurrent translocation t(11; 16) (q23; p13) is associated with therapy-related acute leukemia.17,25 Here we identified that the MLL gene was fused with CBP gene in two patients of MDS with t(11; 16). Our results combined with the finding of the MOZ-CBP fusion in t(8; 16)-AML suggest that the CBP gene may be associated with leukemogenesis through translocations.
| |
MATERIALS AND METHODS |
Patients.
Patient 1, a 2-year-old girl, was diagnosed as refractory anemia with excess of blasts in transformation (RAEB-T). Patient 2, a 6-year-old boy, was initially diagnosed as AML(M2) with t(8; 21)(q22; q22). He achieved a complete remission by chemotherapy including etoposide. After 14 months he developed RAEB-T. Patient samples were obtained at diagnosis from bone marrow (BM) aspirations of both patients with RAEB-T, and their karyotypes showed t(11; 16)(q23; p13) (Fig 1).
View larger version (11K):
[in this window]
[in a new window]
| Fig 1.
Schematic partial karyotype of t(11; 16) (q23; p13). The normal chromosomes of nos. 11 and 16 are on the left in each pair. Arrowheads indicate the breakpoints in the translocation chromosome on the right.
|
|
Cytogenetic studies.
The chromosomes of BM cells from patients 1 and 2 were analyzed by the regular trypsin-Giemsa- or Q-banding method as previously described.16,26
Southern and Northern blot analyses.
High-molecular-weight DNA was extracted from BM cells from patient 1 by proteinase K digestion and phenol/chloroform extraction. Ten micrograms of DNA was digested with appropriate restriction enzymes, subjected to electrophoresis on 0.8% agarose gels, transferred to charged nylon filters (Pall BioSupport, Tokyo, Japan), and hybridized to DNA probes labeled by the random hexamer method.16,19
Poly(A)+ RNA from BM cells of patient 1 was extracted with a Fast Track mRNA Isolation Kit (Invitrogen, San Diego, CA). One microgram of poly (A)+ mRNAs was electrophoresed and transferred onto nylon filters. Blots were hybridized to 32P-labeled probes under the described conditions.19
A 0.9-kb BamHI fragment (designated probe x) derived from MLL cDNA,27 and a 0.5-kb CBP cDNA (nucleotides 701-1197 from patial sequences of CBP cDNA, GenBank accession no. U47741) were used as probes (Fig 2).
View larger version (23K):
[in this window]
[in a new window]
| Fig 2.
Schematic representation of the MLL, CBP, and MLL-CBP fusion proteins, and MLL and CBP cDNA probes and primers (MLL-7S, MLL-11A, CBP-2S, CBP-1A). C/H rich, cysteine/histidine rich; Q rich, glutamine rich. The position of the motifs in CBP were derived from the published protein sequence. The MLL-CBP fusion protein retains the key domains from both proteins.
|
|
Reverse transcriptase-polymerase chain reaction (RT-PCR).
Total cellular RNA was extracted from BM cells of patients 1 and 2 by the acid guanidine isothiocyanate-phenol-chloroform method.28 Four micrograms of total RNA was reverse transcribed to cDNA in a total volume of 20 µL with random hexamers and 20 U of reverse transcriptase (AMV) (Boehringer Mannheim). One twentieth of the cDNA was amplified by PCR in a total volume of 100 µL with 50 mmol/L KCl, 1.5 mmol/L MgCl2 , 10 mmol/L Tris-HCl (pH 9.0 at room temperature), 25 pmol/L of each primer, 75 µmol/L of each dNTP, and 2.5 U of Taq polymerase (Boehringer Mannheim). After 30 rounds of PCR (30 seconds at 94°C, 30 seconds at 55°C, and 1 minute at 72°C), 5 µL of PCR product was electrophoresed in a 3% agarose gel. Primers used were as follows: MLL-7S, 5'-TCCTCAGCACTCTCTCCAAT-3'; MLL-11A, 5'-TTTGCCTGGAGTTGTGGATC-3'; CBP-2S, 5'-TGAATGGATCTCTTGGGGCT-3'; CBP-1A, 5'-GTTTGCTTGCTCTCGTCTCT-3' (Fig 2).
Cloning and sequencing of PCR products.
PCR products were cloned into the TA cloning vector (Invitrogen). Nucleotide sequences were determined by the fluorometric method (Dye Terminator Cycle Sequencing Kit; Applied Biosystems, Urayasu, Japan).
| |
RESULTS |
MLL and CBP genes were involved in t(11; 16)-MDS.
Cells from two children with MDS were cytogenetically characterized as t(11; 16)(q23; p13) (Fig 1). We identified the chromosomal breakpoint within the breakpoint cluster region of MLL gene at 11q23 by Southern blotting using a cDNA probe (probe x) (Figs 2 and 3A) that spans exons 5 through 11 in the MLL locus.27
View larger version (20K):
[in this window]
[in a new window]
View larger version (26K):
[in this window]
[in a new window]
| Fig 3.
(A) Southern blot of DNA digested with EcoRI and probed with the 0.9-kb fragment of the MLL gene. Control, peripheral lymphocytes. Patient 1 exhibited a rearranged band (arrowhead) with this probe. (B) Northern blot of RNAs from patient 1 and a control leukemic cell line (BALM14) using a 0.5-kb CBP cDNA fragment as a probe. Patient 1 showed an abnormal transcript (arrowhead).
|
|
Chromosome 16 band p13 is involved in the chromosomal aberrations, inv(16)(p13q22) and t(8; 16)(p11; p13), in AML. However, the position of the breakpoint at 16p13 in inv(16) differs from that of the t(8; 16).29 To isolate a gene on chromosome 16p13 that fuses to MLL, we performed Southern and Northern blot analyses using a CBP cDNA probe (Fig 2). Blots that were used to detect MLL rearrangements and expression were rehybridized with a probe containing 0.5-kb of the 9-kb CBP cDNA. This probe contains cDNA sequences from both sides of the breakpoint within the CBP cDNA in t(8; 16)-AML and could thus potentially detect both der(11) and der(16). Southern blotting did not detect any rearrangements with CBP cDNA. To clarify the expression of the CBP transcripts, a CBP probe was examined for hybridization to poly(A)+ mRNAs extracted from cells from patient 1, which showed a normal 9-kb CBP transcript and an additional 12-kb transcript (Fig 3B).
Detection of MLL-CBP fusion transcripts.
Using the sense primer on MLL exon 7 (MLL-7S) and the antisense primer on CBP (CBP-1A), we obtained PCR products of 521 bp from patients 1 and 2, and of 407 bp from patient 1 (Fig 4A). Nucleotide sequencing analysis of the three amplified fragments demonstrated 197 bp of MLL exons 7 and 8 in the 5' region, and 324 bp of CBP exon in the 3' region of the longer fragment from both patients, and 83 bp of MLL exon 7 in the 5' region and 324 bp of the CBP exon in the 3' region of the shorter fragment from patient 1 (Fig 4B). These findings indicate that the two chimeric products are generated by alternative splicing at the MLL gene, which was observed in other 11q23 translocations.30 Only in patient 1 were reciprocal PCR products of CBP-MLL fusion transcripts generated by RT-PCR using the sense primer on CBP (CBP-2S) and the antisense primer on MLL exon 11 (MLL-11A) (Fig 4A and B). The fusion transcripts of MLL-CBP commonly observed were considered to play a critical role in the leukemogenesis of t(11; 16)-MDS.
View larger version (68K):
[in this window]
[in a new window]
View larger version (26K):
[in this window]
[in a new window]
| Fig 4.
(A) Identification of fusion transcripts by RT-PCR. Primers used were MLL-7S and CBP-1A (MLL-CBP), and CBP-2S and MLL-11A (CBP-MLL). (B) Partial sequences at the chimeric junctions from five cDNAs (MLL, longer and shorter fragments of MLL-CBP, CBP-MLL, and CBP). longer, longer fragment of 521 bp from patients 1 and 2; shorter, shorter fragment of 407 bp from patient 1. Vertical lines indicate the exon-exon junctions of each gene. Arrows indicate the fusion points of each cDNA.
|
|
| |
DISCUSSION |
The t(11; 16) has thus far been reported in two patients with therapy-related ALL and AML.17,25 Chromosomal breakpoints in 11q23 were detected within the MLL breakpoint cluster region by Southern blotting in both patients. In the present study we first identified that the MLL gene was fused to the CBP gene in two MDS-patients with t(11; 16).
The MLL gene, a human homolog of the Drosophila trithorax gene, encodes a protein of 3,972 amino acids (431 kD) containing zinc fingers and AT-hook motifs.11-13 The incidence of MLL gene rearrangements has been shown to be up to 80% of infant acute leukemia.14-16 MLL gene rearrangements also occur at very high frequency in secondary acute leukemias induced by treating malignancies with inhibitors of topoisomerase II,17,18 suggesting that a reduction in the activity of topoisomerase II is one of the mechanisms for the occurrence of MLL gene rearrangement. It is noted that the MLL gene is fused with various partner genes by 11q23 chromosome translocations. Up to now, 10 partner genes for MLL have been cloned from leukemia cells with various types of reciprocal translocations, including t(4; 11), t(9; 11) and t(11; 19).11-13,19,20 They include the putative transcriptional factors (AF-4, AF-9, AF-10, AF-17, ENL),11,12,20 a target gene for Ras (AF-6),31 and an RNA polymerase II elongation factor (ELL).32 The functions of the normal MLL gene and the fusion transcripts remain unknown. Only one paper reports that chimeric mice carrying the mouse Mll-AF-9 fusion gene developed AML.33 Rearrangements of the MLL gene found in ALL, AML, and MDS suggest that this gene fused with various partner genes plays a causative role in the dysregulation of differentiation along both lymphoid and myeloid pathways.
The CBP, a family of transcriptional coactivator p300, has an adenoviral oncoprotein E1A binding domain and connects the basal transcriptional machinery to transcriptional factors such as the cyclic-adenosine monophosphate responsive element binding protein (CREB).21 CBP normally associates with p300/CBP-associated factor (P/CAF ) having intrinsic histon acetyltransferase activity.34 P/CAF, and also p300, inhibit cell-cycle progression,34 suggesting that CBP may also be involved in the regulation of cell cycle. Moreover, mutations of CBP lead to the development of Rubinstein-Taybi syndrome,22 whose patients have an increased risk of malignant tumors.35 These findings suggest that CBP may be a tumor-suppressor gene. Fusion of CBP to translocated MOZ sequences is associated with specific subtypes of AML with t(8; 16),23,24 and this leukemogenesis may be also associated with dysfunction of CBP.
A schematic representation of the predicted MLL-CBP fusion proteins is shown in Fig 2, with the predicted MLL-CBP fusion transcripts encoding a protein of 3,618 amino acids containing 1,444 amino acids from MLL (amino acids 1 to 1,444) and 2,174 amino acids from CBP (amino acids 267 to 2,440). The MLL-CBP chimeric protein retains the AT-hook domain, DNA methyltransferase homology region, and a transcriptional repression domain of MLL, and the CREB-, E1A-, TFIIB- and P/CAF-binding domains and the acetyltransferase domain36 of CBP. These findings suggest that one possible explanation for leukemogenesis of t(11; 16)-MDS is the disability of CBP to regulate the cell cycle by structural alteration through fusion with MLL. Further functional analysis of the MLL-CBP fusion gene will provide new insights into leukemogenesis by 11q23 chromosomal translocations.
| |
FOOTNOTES |
Submitted February 7, 1997;
accepted March 24, 1997.
Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare of Japan, a Grant-in-Aid for Scientific Research on Priority Areas, and Grant-in-Aid for Scientific Research (B) and (C) from the Ministry of Education, Science, Sports and Culture of Japan.
Address reprint requests to Yasuhide Hayashi, MD, Department of Pediatrics, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113, Japan.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
We thank Prof Y. Igarashi (Department of Pediatrics, Hamamatsu University School of Medicine), Prof M. Yanagisawa (Department of Pediatrics, Faculty of Medicine, University of Tokyo), and I. Kitabayashi (Radiobiology Division, National Cancer Center Research Institute, Tokyo), for their advice and review. We also thank M. Seto (Laboratory of Chemotherapy, Aichi Cancer Center Research Institute) for providing the MLL cDNA probe (probe x), and S. Sohma for her technical assistance.
| |
REFERENCES |
1.
Pui C-H:
Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.
Blood
76:1449,
1990[Abstract/Free Full Text]
2.
Rowley JD:
Molecular cytogenetics: Rosetta stone for understanding cancer  Twenty-ninth G.H.A. Clowes Memorial Award Lecture.
Cancer Res
50:3816,
1990[Free Full Text]
3.
Rabbitts TH:
Chromosomal translocations in human cancer.
Nature
372:143,
1994[Medline]
[Order article via Infotrieve]
4.
Miyoshi H,
Shimizu K,
Kozu T,
Maseki N,
Kaneko Y,
Ohki M:
t(8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.
Proc Natl Acad Sci USA
88:10431,
1991[Abstract/Free Full Text]
5.
Golub TR,
Barker GF,
Bohlander SK,
Hiebert SW,
Ward DC,
Bray-Ward P,
Morgan E,
Raimondi SC,
Rowley JD:
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Proc Natl Acad Sci USA
92:4917,
1995[Abstract/Free Full Text]
6.
Morris SW,
Kirstein MN,
Valentine MB,
Dittmer KG,
Shapiro DN,
Saltman DL,
Look AT:
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science
263:1281,
1994[Abstract/Free Full Text]
7.
Yoneda-Kato N,
Look AT,
Kirstein MN,
Valentine MB,
Raimondi SC,
Cohen KJ,
Carroll AJ,
Morris SW:
The t(3; 5)(q25.1; q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.
Oncogene
12:265,
1996[Medline]
[Order article via Infotrieve]
8.
Ladanyi M,
Gerald W:
Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.
Cancer Res
54:2837,
1994[Abstract/Free Full Text]
9.
Buijs A,
Sherr S,
van Baal S,
van Bezouw S,
van der Plas D,
Geurts van Kessel A,
Riegman P,
Lekanne Deprez R,
Zwarthoff E,
Hagemeijer A:
Translocation (12; 22)(p13; q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.
Oncogene
10:1511,
1995[Medline]
[Order article via Infotrieve]
10.
McCabe NR,
Burnett RC,
Gill HJ,
Thirman MJ,
Mbangkollo D,
Kipiniak M,
van Melle E,
Ziemin-van der Poel S,
Rowley JD,
Diez MO:
Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations.
Proc Natl Acad Sci USA
89:11794,
1992[Abstract/Free Full Text]
11.
Tkachuk DC,
Kohler S,
Cleary ML:
Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.
Cell
71:691,
1992[Medline]
[Order article via Infotrieve]
12.
Gu Y,
Nakamura H,
Alder H,
Prasad R,
Canaani O,
Cimino G,
Croce CM,
Canaani E:
The t(4; 11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.
Cell
71:701,
1992[Medline]
[Order article via Infotrieve]
13.
Djabali M,
Selleri L,
Parry P,
Bower M,
Young BD,
Evans GA:
A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.
Nature Genet
2:113,
1992[Medline]
[Order article via Infotrieve]
14.
Rubnitz JE,
Link MP,
Shuster JJ,
Carroll AJ,
Hakami N,
Frankel LS,
Pullen DJ,
Cleary ML:
Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Blood
84:570,
1994[Abstract/Free Full Text]
15.
Pui C-H,
Kane JR,
Crist WM:
Biology and treatment of infant leukemias.
Leukemia
9:762,
1995[Medline]
[Order article via Infotrieve]
16.
Taki T,
Ida K,
Bessho F,
Hanada R,
Kikuchi A,
Yamamoto K,
Sako M,
Tsuchida M,
Seto M,
Ueda R,
Hayashi Y:
Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia.
Leukemia
10:1303,
1996[Medline]
[Order article via Infotrieve]
17.
Hunger SP,
Tkachuk DC,
Amylon MD,
Link MP,
Carroll AJ,
Welborn JL,
Willman CL,
Cleary ML:
HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.
Blood
81:3197,
1993[Abstract/Free Full Text]
18.
Gill Super HJ,
McCabe NR,
Thirman MJ,
Le Beau MM,
Pedersen-Bjergaard J,
Philip P,
Diez MO,
Rowley JD:
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
Blood
82:3705,
1993[Abstract/Free Full Text]
19.
Taki T,
Hayashi Y,
Taniwaki M,
Seto M,
Ueda R,
Hanada R,
Suzukawa K,
Yokota J,
Morishita K:
Fusion of the MLL gene with two different genes, AF-6 and AF-5 , by a complex translocation involving chromosomes 5, 6, 8, and 11 in infant leukemia.
Oncogene
13:2121,
1996[Medline]
[Order article via Infotrieve]
20.
Rubnitz JE,
Behm FG,
Downing JR:
11q23 rearrangements in acute leukemia.
Leukemia
10:74,
1996[Medline]
[Order article via Infotrieve]
21.
Kwok RPS,
Lundblad JR,
Chrivia JC,
Richards JP,
Bächinger HP,
Brennan RG,
Roberts SGE,
Green MR,
Goodman RH:
Nuclear protein CBP is a coactivator for the transcription factor CREB.
Nature
370:223,
1994[Medline]
[Order article via Infotrieve]
22.
Petrij F,
Giles RH,
Dauwerse HG,
Saris JJ,
Hennekam RCM,
Masuno M,
Tommerup N,
van Ommen G-JB,
Goodman RH,
Peters DJM,
Breuning MH:
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP.
Nature
376:348,
1995[Medline]
[Order article via Infotrieve]
23.
Borrow J,
Stanton VP Jr,
Andresen M,
Becher R,
Behm FG,
Chaganti RSK,
Civin CI,
Disteche C,
Dube I,
Frischauf AM,
Horsman D,
Mitelman F,
Volinia S,
Watmore AE,
Housman DE:
The translocation t(8; 16)(p11; p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.
Nature Genet
14:33,
1996[Medline]
[Order article via Infotrieve]
24.
Reifcnyder C,
Lowell J,
Clarke A,
Pillus L:
Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases.
Nature Genet
14:42,
1996[Medline]
[Order article via Infotrieve]
25.
Roulston D,
Anastasi J,
Rudinsky R,
Nucifora G,
Zeleznik-Le N,
Rowley JD,
McGavran L,
Tsuchida M,
Hayashi Y:
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8; 21): A report of two cases.
Blood
86:3613,
1995[Free Full Text]
26.
Kawamura M,
Kikuchi A,
Kobayashi S,
Hanada R,
Yamamoto K,
Horibe K,
Shikano T,
Ueda K,
Hayashi K,
Sekiya T,
Hayashi Y:
Mutations of the p53 and ras genes in childhood t(1; 19)-acute lymphoblastic leukemia.
Blood
85:2546,
1995[Abstract/Free Full Text]
27.
Yamamoto K,
Seto M,
Komatsu H,
Iida S,
Akao Y,
Kojima S,
Kodera Y,
Nakazawa S,
Ariyoshi Y,
Takahashi T,
Ueda R:
Two distinct portions of LTG19/ENL at 19p13 are involved in t(11; 19) leukemia.
Oncogene
8:2617,
1993[Medline]
[Order article via Infotrieve]
28.
Chomczynski P,
Sacchi N:
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:156,
1987[Medline]
[Order article via Infotrieve]
29.
Wessels JW,
Mollevanger P,
Dauwerse JG,
Cluitmans FHM,
Breuning MH,
Beverstock GC:
Two distinct loci on the short arm of chromosome 16 are involved in myeloid leukemia.
Blood
77:1555,
1991[Abstract/Free Full Text]
30.
Yamamoto K,
Seto M,
Iida S,
Komatsu H,
Kamada N,
Kojima S,
Kodera Y,
Nakazawa S,
Saito H,
Takahashi T,
Ueda R:
A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities.
Blood
83:2912,
1994[Abstract/Free Full Text]
31.
Kuriyama M,
Harada N,
Kuroda S,
Yamamoto T,
Nakafuku M,
Iwamatsu A,
Yamamoto D,
Prasad R,
Croce C,
Canaani E,
Kaibuchi K:
Identification of AF-6 and Canoe as putative targets for Ras.
J Biol Chem
271:607,
1996[Abstract/Free Full Text]
32.
Shilatifard A,
Lane WS,
Jackson KW,
Conaway RC,
Conaway JW:
An RNA polymerase II elongation factor encoded by the human ELL gene.
Science
271:1873,
1996[Abstract]
33.
Corral J,
Lavenir I,
Impey H,
Warren AJ,
Foster A,
Larson TA,
Bell S,
McKerzie ANJ,
King G,
Rabbitts TH:
An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes.
Cell
85:853,
1996[Medline]
[Order article via Infotrieve]
34.
Yang X-J,
Ogryzko VV,
Nishikawa J,
Howard BH,
Nakatani Y:
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.
Nature
382:319,
1996[Medline]
[Order article via Infotrieve]
35.
Miller RW,
Rubinstein JH:
Tumors in Rubinstein-Taybi syndrome.
Am J Med Genet
56:112,
1995[Medline]
[Order article via Infotrieve]
36.
Ogryzko VV,
Schiltz RL,
Russanova V,
Howard BH,
Nakatani Y:
The trascriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953,
1996[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. A. Kimbrel, M. E. Lemieux, X. Xia, T. N. Davis, V. I. Rebel, and A. L. Kung
Systematic in vivo structure-function analysis of p300 in hematopoiesis
Blood,
November 26, 2009;
114(23):
4804 - 4812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Odenike, S. Alkan, D. Sher, J. E. Godwin, D. Huo, S. J. Brandt, M. Green, J. Xie, Y. Zhang, D. H. Vesole, et al.
Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
Clin. Cancer Res.,
November 1, 2008;
14(21):
7095 - 7101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Strehl, K. Nebral, M. Konig, J. Harbott, H. Strobl, R. Ratei, S. Struski, B. Bielorai, M. Lessard, M. Zimmermann, et al.
ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations
Clin. Cancer Res.,
February 15, 2008;
14(4):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Nguyen, P. P. Pandolfi, Y. Aikawa, Y. Tagata, M. Ohki, and I. Kitabayashi
Physical and functional link of the leukemia-associated factors AML1 and PML
Blood,
January 1, 2005;
105(1):
292 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-J. Yang
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Nucleic Acids Res.,
February 11, 2004;
32(3):
959 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Glassman and K. J. Hayes
Translocation (11;16)(q23;p13) Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Ann. Clin. Lab. Sci.,
July 1, 2003;
33(3):
285 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hirai
Molecular Mechanisms of Myelodysplastic Syndrome
Jpn. J. Clin. Oncol.,
April 1, 2003;
33(4):
153 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. So and M. L. Cleary
MLL-AFX Requires the Transcriptional Effector Domains of AFX To Transform Myeloid Progenitors and Transdominantly Interfere with Forkhead Protein Function
Mol. Cell. Biol.,
September 15, 2002;
22(18):
6542 - 6552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ono, T. Taki, T. Taketani, M. Taniwaki, H. Kobayashi, and Y. Hayashi
LCX, Leukemia-associated Protein with a CXXC Domain, Is Fused to MLL in Acute Myeloid Leukemia with Trilineage Dysplasia Having t(10;11)(q22;q23)
Cancer Res.,
July 15, 2002;
62(14):
4075 - 4080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Dash, I. R. Williams, J. L. Kutok, M. H. Tomasson, E. Anastasiadou, K. Lindahl, S. Li, R. A. Van Etten, J. Borrow, D. Housman, et al.
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
PNAS,
May 28, 2002;
99(11):
7622 - 7627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. DiMartino, P. M. Ayton, E. H. Chen, C. C. Naftzger, B. D. Young, and M. L. Cleary
The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10
Blood,
May 15, 2002;
99(10):
3780 - 3785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Blobel
CBP and p300: versatile coregulators with important roles in hematopoietic gene expression
J. Leukoc. Biol.,
April 1, 2002;
71(4):
545 - 556.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Murata, R. Kurokawa, A. Krones, K. Tatsumi, M. Ishii, T. Taki, M. Masuno, H. Ohashi, M. Yanagisawa, M. G. Rosenfeld, et al.
Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome
Hum. Mol. Genet.,
May 1, 2001;
10(10):
1071 - 1076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ernst, J. Wang, M. Huang, R. H. Goodman, and S. J. Korsmeyer
MLL and CREB Bind Cooperatively to the Nuclear Coactivator CREB-Binding Protein
Mol. Cell. Biol.,
April 1, 2001;
21(7):
2249 - 2258.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. Panagopoulos, T. Fioretos, M. Isaksson, U. Samuelsson, R. Billstrom, B. Strombeck, F. Mitelman, and B. Johansson
Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13)
Hum. Mol. Genet.,
February 1, 2001;
10(4):
395 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Sterner and S. L. Berger
Acetylation of Histones and Transcription-Related Factors
Microbiol. Mol. Biol. Rev.,
June 1, 2000;
64(2):
435 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Pao, R. Janknecht, H. Ruffner, T. Hunter, and I. M. Verma
CBP/p300 interact with and function as transcriptional coactivators of BRCA1
PNAS,
February 1, 2000;
97(3):
1020 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hayashi, Y. Honma, N. Niitsu, T. Taki, F. Bessho, M. Sako, T. Mori, M. Yanagisawa, K. Tsuji, and T. Nakahata
SN-1, A Novel Leukemic Cell Line with t(11;16)(q23;p13): Myeloid Characteristics and Resistance to Retinoids and Vitamin D3
Cancer Res.,
February 1, 2000;
60(4):
1139 - 1145.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. A. Blobel
CREB-binding protein and p300: molecular integrators of hematopoietic transcription
Blood,
February 1, 2000;
95(3):
745 - 755.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Taki, H. Kano, M. Taniwaki, M. Sako, M. Yanagisawa, and Y. Hayashi
AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23)
PNAS,
December 7, 1999;
96(25):
14535 - 14540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T. Adler, R. Chinery, D. Y. Wu, S. J. Kussick, J. M. Payne, A. J. Fornace Jr., and D. C. Tkachuk
Leukemic HRX Fusion Proteins Inhibit GADD34-Induced Apoptosis and Associate with the GADD34 and hSNF5/INI1 Proteins
Mol. Cell. Biol.,
October 1, 1999;
19(10):
7050 - 7060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Champagne, N. R. Bertos, N. Pelletier, A. H. Wang, M. Vezmar, Y. Yang, H. H. Heng, and X.-J. Yang
Identification of a Human Histone Acetyltransferase Related to Monocytic Leukemia Zinc Finger Protein
J. Biol. Chem.,
October 1, 1999;
274(40):
28528 - 28536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Taki, H. Ohnishi, K. Shinohara, M. Sako, F. Bessho, M. Yanagisawa, and Y. Hayashi
AF17q25, a Putative Septin Family Gene, Fuses the MLL Gene in Acute Myeloid Leukemia with t(11;17)(q23;q25)
Cancer Res.,
September 1, 1999;
59(17):
4261 - 4265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Redner, J. Wang, and J. M. Liu
Chromatin Remodeling and Leukemia: New Therapeutic Paradigms
Blood,
July 15, 1999;
94(2):
417 - 428.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Felix and B. J. Lange
Leukemia in Infants
Oncologist,
June 1, 1999;
4(3):
225 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Osaka, J. D. Rowley, and N. J. Zeleznik-Le
MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25)
PNAS,
May 25, 1999;
96(11):
6428 - 6433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Maki, K. Mitani, T. Yamagata, M. Kurokawa, Y. Kanda, Y. Yazaki, and H. Hirai
Transcriptional Inhibition of p53 by the MLL/MEN Chimeric Protein Found in Myeloid Leukemia
Blood,
May 15, 1999;
93(10):
3216 - 3224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Kasper, P. K. Brindle, C. A. Schnabel, C. E. J. Pritchard, M. L. Cleary, and J. M. A. van Deursen
CREB Binding Protein Interacts with Nucleoporin-Specific FG Repeats That Activate Transcription and Mediate NUP98-HOXA9 Oncogenicity
Mol. Cell. Biol.,
January 1, 1999;
19(1):
764 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Taki, N. Shibuya, M. Taniwaki, R. Hanada, K. Morishita, F. Bessho, M. Yanagisawa, and Y. Hayashi
ABI-1, a Human Homolog to Mouse Abl-Interactor 1, Fuses the MLL Gene in Acute Myeloid Leukemia With t(10;11)(p11.2;q23)
Blood,
August 15, 1998;
92(4):
1125 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Megonigal, E. F. Rappaport, D. H. Jones, T. M. Williams, B. D. Lovett, K. M. Kelly, P. H. Lerou, T. Moulton, M. L. Budarf, and C. A. Felix
t(11;22)(q23;q11.2) in acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes
PNAS,
May 26, 1998;
95(11):
6413 - 6418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Carapeti, R. C.T. Aguiar, J. M. Goldman, and N. C.P. Cross
A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia
Blood,
May 1, 1998;
91(9):
3127 - 3133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guidez, S. Ivins, J. Zhu, M. Soderstrom, S. Waxman, and A. Zelent
Reduced Retinoic Acid-Sensitivities of Nuclear Receptor Corepressor Binding to PML- and PLZF-RARalpha Underlie Molecular Pathogenesis and Treatment of Acute Promyelocytic Leukemia
Blood,
April 15, 1998;
91(8):
2634 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Slany, C. Lavau, and M. L. Cleary
The Oncogenic Capacity of HRX-ENL Requires the Transcriptional Transactivation Activity of ENL and the DNA Binding Motifs of HRX
Mol. Cell. Biol.,
January 1, 1998;
18(1):
122 - 129.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R.J. LIN, H.-Y. KAO, P. ORDENTLICH, and R.M. EVANS
The Transcriptional Basis of Steroid Physiology
Cold Spring Harb Symp Quant Biol,
January 1, 1998;
63(0):
577 - 586.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J. Nevrivy, and M. Leid
p300 Functions as a Coactivator for the Peroxisome Proliferator-activated Receptor alpha
J. Biol. Chem.,
December 26, 1997;
272(52):
33435 - 33443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ida, I. Kitabayashi, T. Taki, M. Taniwaki, K. Noro, M. Yamamoto, M. Ohki, and Y. Hayashi
Adenoviral E1A-Associated Protein p300 Is Involved in Acute Myeloid Leukemia With t(11; 22)(q23; q13)
Blood,
December 15, 1997;
90(12):
4699 - 4704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Kersey
Fifty Years of Studies of the Biology and Therapy of Childhood Leukemia
Blood,
December 1, 1997;
90(11):
4243 - 4251.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T. Adler, F. S. Nallaseth, G. Walter, and D. C. Tkachuk
HRX Leukemic Fusion Proteins Form a Heterocomplex with the Leukemia-associated Protein SET and Protein Phosphatase 2A
J. Biol. Chem.,
November 7, 1997;
272(45):
28407 - 28414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Sobulo, J. Borrow, R. Tomek, S. Reshmi, A. Harden, B. Schlegelberger, D. Housman, N. A. Doggett, J. D. Rowley, and N. J. Zeleznik-Le
MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3)
PNAS,
August 5, 1997;
94(16):
8732 - 8737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Kourlas, M. P. Strout, B. Becknell, M. L. Veronese, C. M. Croce, K. S. Theil, R. Krahe, T. Ruutu, S. Knuutila, C. D. Bloomfield, et al.
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: Evidence for its fusion with MLL in acute myeloid leukemia
PNAS,
February 29, 2000;
97(5):
2145 - 2150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract